Small Intestinal Function in Patients With Cystic Fibrosis

This study is enrolling participants by invitation only.
Sponsor:
Information provided by (Responsible Party):
University of Aarhus
ClinicalTrials.gov Identifier:
NCT01468428
First received: November 7, 2011
Last updated: November 10, 2011
Last verified: November 2011

November 7, 2011
November 10, 2011
October 2010
December 2011   (final data collection date for primary outcome measure)
Small intestinal transit time [ Designated as safety issue: No ]
MTS-1: A small magnet pill is ingested and its movements are monitored and recorded from mouth to caecum. The transit time of the stomach and small intestine is determined by real-time recordings.
Same as current
Complete list of historical versions of study NCT01468428 on ClinicalTrials.gov Archive Site
Colorectal transit time [ Designated as safety issue: No ]
Colorectal transit times are obtained using a plain abdominal x-ray after subjects has ingested 10 radiopaque markers on six consecutive days up to examination. The total number of markers in the entire colorectrum is counted and total as well as segmental transit times are calculated.
Same as current
Not Provided
Not Provided
 
Small Intestinal Function in Patients With Cystic Fibrosis
Small Intestinal Function in Patients With Cystic Fibrosis

In patients with Cystic fibrosis (CF) epithelial transport of chloride and sodium is disrupted in several organs such as airways, sweat glands, pancreas and intestines. Gastrointestinal symptoms are frequent but little is known about intestinal motility and function. Earlier studies using lactulose/hydrogen breath tests have found altered intestinal transit time. The method has several sources of errors and results have been questioned. This study is using a new, non invasive method to study intestinal motility patterns and transit times, Magnetic Tracking System - 1 (MTS-1).

The aim is to compare patterns of contractility and transit times in the stomach and small intestine in adult CF- patients with healthy controls.

Methods MTS-1 is performed without radiation and is associated with minimal discomfort for subjects. A small magnetic pill is ingest and detected by a matrix of sensors. Position and orientation of the magnet are defined by five coordinates (position: x, y, z, angle: φ, θ). Frequencies of slow waves as well as number and power of phase III contractions can be identified.

Colorectal transit times are determined with a plain abdominal x-ray. The subjects are asked to ingest a capsule containing 10 radiopaque markers on six consecutive days up to examination. The total number of markers in the entire colorectum is counted. Total transit time, as well as segmental is calculated.

Subjects 15 adult patients (> 18 years) with CF, homozygote for the mutation ΔF508, are studied. They are all pancreas insufficient (fecal elastase < 100 µg/g), with no previous intestinal resection or lung transplantation. None of them have diabetes. Patients are all in well-regulated pancreatic enzyme replacement therapy (PERT), thriving and with stabile weight over the last half year. They have had no treatment with antibiotics in the last 14 days up to the examination.

The hypothesis is that patterns of contractility and transit times are the same for CF-patients in well -regulated PERT as for healthy controls.

Not Provided
Observational
Observational Model: Case Control
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
  • 15 CF patients with severe mutations and pancreatic insufficiency, without having diabetes or intestinal resection, with stable weight and no antibiotic treatment 14 days up to examination.
  • 15 age- and gender matched healthy controls
  • Cystic Fibrosis
  • Gastrointestinal Motility
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Enrolling by invitation
15
December 2011
December 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Cystic fibrosis, severe mutations
  • Pancreatic insufficiency(Fecal elastase < 100 µg/g)
  • Thriving, stabile weight over the last half year
  • No treatment with antibiotics in the last 14 days up to the examination

Exclusion Criteria:

  • intestinal resection
  • lung transplantation
  • diabetes
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Denmark
 
NCT01468428
UAarhus - VCF
Yes
University of Aarhus
University of Aarhus
Not Provided
Not Provided
University of Aarhus
November 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP